Dumyrox 100 mg fluvoxamine maleate

Dumyrox is a brand of fluvoxamine maleate, a selective serotonin reuptake inhibitor (SSRI) used primarily to treat major depressive disorder and obsessive-compulsive disorder (OCD). The product shown in the image is a 100 mg film-coated tablet produced for the Greek market, as indicated by the Greek text on the packaging.

The history of the drug dates back to its development by the Dutch company Kali-Duphar, which was later acquired by Solvay Pharmaceuticals (Belgium). In 2010, Abbott Laboratories acquired Solvay's pharmaceutical division. Eventually, the rights to many of these established brands, including Dumyrox and its siblings like Dumirox and Luvox, moved through strategic acquisitions. Mylan acquired Abbott’s branded specialty and generic business in developed markets in 2015. In November 2020, Mylan merged with Pfizer's Upjohn division to form Viatris, the current ultimate owner of the brand.

Manufacturing of Dumyrox and its generic equivalents occurs across several global facilities. While major production hubs for Viatris are located in countries such as India, Ireland, and Australia, the specific supply for the European market often involves regional manufacturing or distribution hubs in Spain and Portugal.